Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 1 clinical trial titled A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects With Advanced Solid Tumors. The study aims to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and determine the maximum tolerated dose or recommended Phase 2 dose when used alone or with ABBV-181 in patients with advanced solid tumors.
The interventions being tested include ABBV-927, administered intravenously or intratumorally, and ABBV-181, administered intravenously. These drugs are designed to treat advanced solid tumors, including non-small cell lung cancer and head and neck squamous cell carcinoma.
The study is interventional with a non-randomized, sequential model and no masking, focusing on treatment. It started on February 22, 2017, and the last update was submitted on August 7, 2025. The primary completion and estimated completion dates have not been provided.
The market implications of this study could be significant for AbbVie, potentially boosting investor confidence and stock performance if the results are favorable. As the study progresses, it may impact the competitive landscape in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.